Navigation Links
DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma
Date:3/31/2008

Completion of Target Enrollment Expected in Fourth Quarter

BERKELEY HEIGHTS, N.J., March 31 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced that the Data Safety Monitoring Board (DSMB) for AGENDA, a Phase 3 trial of Genasense (oblimersen sodium) Injection, which is the Company's lead oncology product, has recommended that the trial be continued as originally planned after initial review of blinded safety data from the study.

AGENDA is a Phase 3, randomized, double-blind, placebo-controlled trial that is intended to support global registration of Genasense for patients with advanced melanoma. The study is designed to confirm certain safety and efficacy results from Genta's prior randomized trial of Genasense combined with dacarbazine (DTIC) in patients identified by a biomarker who have not previously received chemotherapy. The co-primary endpoints of AGENDA are progression-free survival and overall survival.

At the end of the first quarter, the trial had accrued approximately 50 patients with approximately 60% of planned investigative sites having been initiated. Countries with sites currently open for enrollment include the U.S., Canada, Australia, France, Germany, Austria, and the Czech Republic. The trial is planned to open at approximately 90 sites worldwide, and most remaining sites are expected to initiate within the next 30 days. Target accrual of 300 patients is expected to complete in the fourth quarter of 2008, with initial data expected shortly thereafter.

"Investigator enthusiasm for AGENDA is quite high, and we are currently recruiting at our expected rate," said Dr. Loretta M. Itri, M.D., Genta's President, Pharmaceutical Development. "We believe the current rate, combin
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. DSMB Again Supports Continuation of the Phase III Clinical Trial of Medidur(TM) FA for the Treatment of DME
2. Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention
3. ACR Supports American Cancer Society Inclusion of CT Colonography (Virtual Colonoscopy) as Recommended Screening Tool for Colorectal Cancer in New Screening Guidelines
4. New Clinical Data Further Supports Chromium Picolinates Role in Enhancing Brain Activity in Older Adults
5. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
6. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
7. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
8. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
9. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
10. New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease
11. Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... R.I. , July 25, 2014  CVS Caremark ... a conference call on Tuesday, August 5, 2014, at ... its second quarter 2014 financial results. An ... simultaneously through the Investor Relations portion of the CVS ... webcast, visit http://info.cvscaremark.com/investors . This webcast will be ...
(Date:7/25/2014)... Cardinal Health will today name three of ... its prestigious Independent Pharmacy Best Practices Competition, during the ... nation,s largest gatherings of independent pharmacists. ... Ohio , Tennessee ... selected for implementing exceptionally creative methods that demonstrate how ...
(Date:7/25/2014)... York , July 25, 2014 ... Transparency Market Research "Global and China Insulin Market (Rapid-Acting, ... Industry Analysis, Size, Share, Growth, Trends and Forecast (Value ... was valued at USD 19.99 billion in 2012 and ... from 2013 to 2019 to reach USD 32.24 billion ...
Breaking Medicine Technology:Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 2Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 3Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 4Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 5Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 6Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4
(Date:7/25/2014)... (HealthDay News) -- Unlike children, the vast majority of adults ... at mealtime, according to a new study. This ... not just Americans, researchers from Cornell University revealed. They ... or improve their eating habits make better choices. "If ... stomach," researcher Brian Wansink, director of the Cornell Food ...
(Date:7/25/2014)... 2014 (HealthDay News) -- Although cervical cancers are declining ... to human papillomavirus (HPV) are increasing, a new study ... base of the tongue and tonsils have increased over ... younger than 45, the Canadian researchers report. "The ... younger men and of anal cancer among younger women ...
(Date:7/25/2014)... that controls when genes are switched on or off ... brain to regulate metabolism, UT Southwestern Medical Center researchers ... therapies to treat obesity and diabetes, since the transcription ... appears to influence the body,s sensitivity to insulin ... to the body,s regulation of food intake and sugar ...
(Date:7/25/2014)... NH (PRWEB) July 25, 2014 Innerspire, ... has joined the company as a Creative Enrollment Specialist. ... extensive relationship building skills as well as his accomplished ... of small business clients, and to service the creative ... Additionally, Greg will work with small business owners ...
(Date:7/25/2014)... American Brain Tumor Association (ABTA) today unveiled branding of ... patient and family conference in Chicago. , “This is ... we – the first and now only national organization ... tumor research – extend our reach by engaging volunteers ... our materials and services into the hands of those ...
Breaking Medicine News(10 mins):Health News:Most Adults Are Members of 'Clean Plate Club' 2Health News:Anal, Throat Cancers on the Rise Among Young Adults, Study Finds 2Health News:Manipulating key protein in the brain holds potential against obesity and diabetes 2Health News:Innerspire, LLC Continues National Expansion 2Health News:Innerspire, LLC Continues National Expansion 3Health News:Innerspire, LLC Continues National Expansion 4Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 2Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 3
... Include 24-oz and Convenient 4-oz Travel Size Spray ... PURE ) today announced an agreement ... silver dihydrogen citrate (SDC)-based disinfectant as OneShot Plus(TM) ... Plus product line. OneShot Plus DD eliminates ...
... retire from BoardNATICK, Mass., March 2 Boston Scientific Corporation ... Board of Directors has elected John E. Sununu as a ... as a U.S. Senator from New Hampshire. He was ... Foreign Relations, and he was appointed the Congressional Representative to ...
... no harm -- from TV viewing by young children, , , MONDAY, ... a shelf full of videos claiming to be educationally stimulating for ... wallet. , A new study suggests that watching television won,t ... several hours a day. , "TV, in and of itself, ...
... Officially Launched to Provide Consumers a Free-of-Charge ... from Funeral Homes, Cremation Services and Cemeteries ... http://www.FuneralDecisions.com ) has announced the official launch ... tool for individuals seeking funeral, cremation, and ...
... System Cart Allows Easier Operation and Improved Workflow ... Traxtal Inc., the pioneer and world leader in ... newly designed system cart for the PercuNav interventional ... Booth # 322 of the Society of Interventional ...
... March 2 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. ... today announced that the Company has amended the ... facility with Valens U.S. (formerly Laurus Master Funds). ... agreed to a near-term extension of this facility, ...
Cached Medicine News:Health News:Sterifide Laboratories to Launch 'Powered by SDC' OneShot Plus Disinfectant and Deodorizer 2Health News:Sterifide Laboratories to Launch 'Powered by SDC' OneShot Plus Disinfectant and Deodorizer 3Health News:Sterifide Laboratories to Launch 'Powered by SDC' OneShot Plus Disinfectant and Deodorizer 4Health News:Boston Scientific Announces Election Of John Sununu To Its Board Of Directors 2Health News:Boston Scientific Announces Election Of John Sununu To Its Board Of Directors 3Health News:Boston Scientific Announces Election Of John Sununu To Its Board Of Directors 4Health News:TV Watching Doesn't Fast-Track Baby's Skills 2Health News:TV Watching Doesn't Fast-Track Baby's Skills 3Health News:Taking the Stress Out of Funeral Planning, FuneralDecisions.com Offers Consumers an Innovative Approach 2Health News:Traxtal to Introduce Next-Generation PercuNav System Cart at SIR Annual Scientific Meeting 2Health News:Bioniche Revolving Credit Facility Maturity Date Amended 2
... The Clariflex® Intraocular Lens is indicated ... years of age or older in whom ... IOL is a third-generation IOL design made ... is designed both to reduce internal reflections ...
... Chamber Lenses: The Bausch & Lomb PMMA Posterior ... for primary implantation for the visual correction of ... older where a cataractous lens has been removed ... to be placed in the ciliary sulcus or ...
... All USIOL lenses are manufactured ... and processes. Perspex CQ UV ... the multi-piece and single piece ... available in both nonphaco and ...
... sterile nonpyrogenic, transparent viscoelastic solution of highly ... mg/ml of high molecular weight (greater than ... physiological saline. In the limit of zero ... (105 Pa s) at 25 C and ...
Medicine Products: